文献速递中枢神经肿瘤放疗放疗物理与技术

澳大利亚1.5T MR-Linac引导自适应放疗治疗胶质母细胞瘤的临床结局与生活质量

Clinical outcomes and quality of life in glioblastoma patients treated with MR-guided adaptive radiotherapy using a 1.5 T MR-Linac in an Australian setting.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-02-19

该单中心研究纳入27例胶质母细胞瘤患者,于2021年8月至2024年5月接受1.5T MR-Linac自适应放疗。中位随访12.2个月,中位总生存期14.1个月、无进展生存期11.2个月,未报告3-4级毒性,生活质量在3个月时下降、6个月时恢复。

要点

  • 27例胶质母细胞瘤患者接受1.5T MR-Linac自适应放疗,中位OS 14.1个月、PFS 11.2个月。
  • 11例(39.3%)因肿瘤进展需Adapt-To-Shape或重新计划,未报告3-4级毒性。
  • 生活质量3个月时下降、6个月时恢复,中位在床治疗时间28.2分钟。

核心结论

  • MR引导自适应放疗治疗胶质母细胞瘤可行,急性毒性可控,并能根据肿瘤变化进行自适应调整。

研究设计与样本

  • 单中心研究纳入2021年8月至2024年5月接受1.5T MR-Linac治疗的27例胶质母细胞瘤患者,中位随访12.2个月。

主要发现

  • 中位OS为14.1个月,中位PFS为11.2个月。
  • 11例(39.3%)在第一周内因T2/FLAIR信号超出初始CTV提示肿瘤进展而需要Adapt-To-Shape或重新计划。
  • 未报告3-4级毒性,生活质量在3个月时下降、6个月时恢复。
  • 26例完成MR-Linac上全部处方分次,每分次中位在床治疗时间28.2分钟(范围11.7-66.5分钟)。

关键数值与推荐

  • 患者平均年龄63岁,14例为男性且ECOG体力状态为0-1。
  • 11例接受全切除,9例次全切除,7例仅活检;11例MGMT甲基化,15例非甲基化,1例状态未知。
  • 从CT/MRI模拟定位到放疗开始平均间隔12.6天。

临床怎么用

  • 对于胶质母细胞瘤,可考虑采用1.5T MR-Linac进行自适应放疗,并关注第一周内肿瘤进展导致的重计划需求。
  • 治疗期间应评估生活质量变化,关注3个月时下降及6个月恢复的趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The magnetic resonance linear accelerator (MRL) enables daily adaptation of radiation therapy plans. This study presents our institutional experience with the clinical outcomes and quality of life (QoL) of glioblastoma patients treated using a 1.5 Tesla (T) MRL. MATERIALS AND METHODS: Eligible patients with glioblastoma were enrolled in a study and treated with MRL between August 2021 and May 2024. Acute toxicity was assessed. QoL was evaluated using the EORTC QLQ-C30 and QLQ-BN20 questionnaires. Cumulative overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier analysis. RESULTS: 27 patients were included, with a median follow-up of 12.2 months (range 0.5-30.6 months). The mean age was 63 years; 14 were male and had an ECOG performance status of 0-1. Eleven patients underwent gross total resection, 9 had subtotal resection, and 7 had biopsy only. 11 were MGMT-methylated, 15 nonmethylated, and 1 had unknown status. Twenty-five received their first radiotherapy course on the MRL. The mean interval from CT/MRI simulation to radiotherapy start was 12.6 days. 26 patients completed all prescribed fractions on the MRL. The median on-table treatment time per fraction was 28.2 (range: 11.7-66.5) minutes. Eleven patients (39.3%) required Adapt-To-Shape or re-planning within the first week due to tumor progression, indicated by increased T2/FLAIR signal beyond the initial CTV. No Grade 3-4 toxicities were reported. At 3 months, treatment was associated with declines in QoL domains at 3 months with recovery by 6 months. The median OS and PFS were 14.1 and 11.2 months. CONCLUSION: Treatment of glioblastoma with MR-guided adaptive radiotherapy is feasible, with manageable acute toxicities and adaptive capabilities to address tumor changes.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jamora K, Wada M, Khor R, et al. Clinical outcomes and quality of life in glioblastoma patients treated with MR-guided adaptive radiotherapy using a 1.5 T MR-Linac in an Australian setting. Clin Transl Radiat Oncol. 2026. PMID: 41756144. doi:10.1016/j.ctro.2026.101132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。